Urothelial Cancer Clinical Trials

Find Urothelial Cancer Clinical Trials Near You

Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

To evaluate the ability of \[68Ga\]N188 to detect nectin-4 overexpression in patients with urothelial carcinoma, especially in patients with recurrent or advanced bladder cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:

• 18-75 years old, male or female;

• Heart function is normal;

• Normal heart function;

• Estimated survival ≥12 weeks;

• Good follow-up compliance;

• presence of at least one measurable target lesion according to RECIST1.1 criteria;

• Women of childbearing age (15-49 years) must have a negative pregnancy test within 7 days before starting the test; Fertile men and women must agree to use effective contraception to prevent pregnancy during the study period and for 3 months after the test;

• Patients recommended by clinicians to undergo PET/CT examination for tumor diagnostic staging;

• The subject patients could fully understand and voluntarily participate in the experiment, and signed the informed consent.

Locations
Other Locations
China
Beijing Cancer Hospital
RECRUITING
Beijing
Contact Information
Primary
Zhi Yang, Professor
pekyz@163.com
010-88196495
Backup
Hua Zhu, Professor
zhuhuabch@pku.edu.cn
010-88196495
Time Frame
Start Date: 2026-05-31
Estimated Completion Date: 2026-12
Participants
Target number of participants: 20
Treatments
Experimental: 68Ga-N188
Imaging cohort All study participants will be allocated to this arm (single-arm study). Study participants will undergo 68Ga-N188 PET/CT scan.
Related Therapeutic Areas
Sponsors
Leads: Peking University Cancer Hospital & Institute

This content was sourced from clinicaltrials.gov